Table 2.
Antimicrobial resistance rate (%) of Mh infection in patients
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| Case (%) | Case (%) | Case (%) | Case (%) | Case (%) | |
| TET | 0 (0.0) | 2 (12.5) | 3 (13.6) | 1 (3.4) | 14 (17.5) |
| LEV | 2 (40.0) | 5 (31.3) | 8 (36.4) | 9 (31.0) | 39 (48.8) |
| ERY | 5 (100.0) | 15 (93.8) | 20 (90.9) | 28 (96.6) | 65 (81.3) |
| JOS | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.3) |
| DOX | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| CIP | 3 (60.0) | 9 (56.3) | 11 (50.0) | 13 (44.8) | 48 (60.0) |
| OFX | 1 (20.0) | 6 (37.5) | 7 (31.8) | 9 (31.0) | 31 (38.8) |
| MIN | 0 (0.0) | 0 (0.0) | 1 (4.5) | 0 (0.0) | 2 (2.5) |
| ROX | 5 (100.0) | 16 (100.0) | 20 (90.9) | 28 (96.6) | 73 (91.3) |
| AZM | 5 (100.0) | 16 (100.0) | 20 (90.9) | 28 (96.6) | 73 (91.3) |
| CLR | 5 (100.0) | 15 (93.8) | 21 (95.5) | 28 (96.6) | 69 (86.3) |
| SPA | 2 (40.0) | 6 (37.5) | 7 (31.8) | 8 (27.6) | 25 (31.3) |
| n | 5 | 16 | 22 | 29 | 80 |
Abbreviations: AZM, azithromycin; CIP, ciprofloxacin; CLR, clarithromycin; DOX, doxycycline; ERY, erythromycin; JOS, josamycin; LEV, levofloxacin; Mh, Mycoplasma hominis; MIN, minocycline; OFX, ofloxacin; ROX, roxithromycin; SPA, sparfloxacin; TET, tetracycline.